Korro Bio (KRRO) Director Formela Jean Francois Sells Shares

What Happened
Formela Jean Francois, a director of Korro Bio, sold a total of 48,690 shares in open-market transactions on September 11 and September 14, 2026, for aggregate proceeds of approximately $686,178. Breakout by trade:

• 2026-09-11: 8,450 shares at $13.99 — $118,216 (disposed)
• 2026-09-11: 1,750 shares at $13.99 — $24,483 (disposed)
• 2026-09-14: 31,888 shares at $14.12 — $450,259 (disposed)
• 2026-09-14: 6,602 shares at $14.12 — $93,220 (disposed)

These were sales (not purchases), and at least some were executed under a pre-established Rule 10b5-1 trading plan (see footnote).

Key Details

• Transaction dates and reported prices: Sept 11 (weighted avg $13.99; individual trades ranged $13.95–$14.02 per footnote), Sept 14 (weighted avg $14.12; trades ranged $13.95–$14.59 per footnote).
• Total shares sold: 48,690; total proceeds: ~$686,178.
• Footnotes: F1 indicates shares were sold pursuant to a Rule 10b5-1 plan adopted April 8, 2026. F2 and F5 note the reported prices are weighted averages and the filer will provide breakdowns on request. F3 and F4 state certain shares are held by Atlas venture funds and the reporting person disclaims Section 16 beneficial ownership of those fund-held shares except for any pecuniary interest.
• Shares owned after the transactions: not specified in the provided data.
• Timeliness: Form 4 was filed on 2026-09-15; based on the trade dates (Sept 11 and Sept 14) this filing appears timely within the SEC’s reporting window.

Context

• Sales executed under a Rule 10b5-1 plan are planned transactions and are generally considered routine (they do not necessarily signal a change in the insider’s view of the company).
• These are straight sales (transaction code S). For retail investors, purchases are often more informative about insider sentiment; sales can reflect diversification, planned liquidity, or other personal reasons and should be interpreted cautiously.